Human Relaxin-2
Also known as: Human Relaxin-2, Relaxin-2, Serelaxin
Human Relaxin-2 is a peptide hormone with vasodilatory and anti-fibrotic properties, also developed clinically as serelaxin. It is studied for cardiovascular and tissue-remodeling research.
Last updated
Mechanism of Action
Relaxin-2 is a two-chain insulin-superfamily peptide that signals primarily through the RXFP1 G-protein-coupled receptor. Receptor activation raises cAMP and stimulates nitric-oxide and endothelin-pathway signaling, producing systemic vasodilation and increased arterial compliance. Relaxin-2 also downregulates pro-fibrotic TGF-beta signaling and activates matrix metalloproteinases, reducing collagen deposition and promoting tissue remodeling. These combined hemodynamic and anti-fibrotic actions drive its research interest in heart failure and fibrotic conditions.
- Half-life
- Short circulating half-life; clinical serelaxin given as continuous infusion
- Administration Routes
- subcutaneous
- Research Status
- Clinical
Reported Benefits
- Promotes systemic vasodilation and improved vascular compliance
- Exhibits anti-fibrotic activity by reducing collagen deposition
- Investigated for acute heart failure in clinical trials
- Supports connective-tissue remodeling research
- Studied for renal and hepatic anti-fibrotic effects
Potential Side Effects
- Hypotension from vasodilation
- Headache
- Dizziness
- Possible reflex changes in heart rate
Common Dosing
Clinical serelaxin studies used continuous intravenous infusion dosed by micrograms per kilogram per day; no validated subcutaneous protocol exists. Presented for research-use context only and not personal medical advice.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Significant hypotension or hemodynamic instability
- Use outside controlled research or clinical settings
- Caution with other vasodilators
- View
Serelaxin and acute heart failure
2016
- View
Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial
2013
- View
Effects of Serelaxin in Patients with Acute Heart Failure
2019
- View
Cardiovascular effects of relaxin-2: therapeutic potential and future perspectives
2024
- View
Relaxin as a treatment for musculoskeletal fibrosis: What we know and future directions
2024